Please assess the completion status of the following clinical trial:

Trial Title: ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD (chronic obstructive pulmonary disease).~* Current or previous cigarette smokers with a smoking history of at least 10 pack-years.~* History of a least 1 COPD exacerbation in the 12 months prior to screening.~* Forced expiratory volume in one second (FEV1) of less than or equal to 50% of predicted normal.~Exclusion Criteria:~* Current diagnosis of asthma.~* Additional respiratory disorders other than COPD (eg, sarcoidosis, alpha-1 antitrypsin deficiency, cystic fibrosis, or active tuberculosis).~* Concurrent use of long-acting beta-agonists, long-acting anticholinergics, inhaled and oral corticosteroids, theophylline, investigational medications, ritonavir, and anti-leukotrienes.~* Lung resection surgery within 1 year of screening.~* Abnormal and clinically significant ECG findings at screening.~* Other inclusion and exclusion criteria will be evaluated at the first study visit.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).